A Poujois1,2, J-M Trocello1,2, N Djebrani-Oussedik1,3, J Poupon1,3, C Collet1,4, N Girardot-Tinant1,2, R Sobesky1,5, D Habès1,6, D Debray7, C Vanlemmens8, F Fluchère9, F Ory-Magne10, J Labreuche11, C Preda12, F Woimant1,2. 1. National Reference Centre for Wilson's Disease, AP-HP, Lariboisière Hospital, Paris, France. 2. Neurology Department, AP-HP, Lariboisière Hospital, Paris, France. 3. Toxicology Laboratory, AP-HP, Lariboisière Hospital, Paris, France. 4. Molecular Biology and Biochemistry Department, AP-HP, Lariboisière Hospital, Paris, France. 5. Hepatobiliary Centre, DHU Hepatinov, AP-HP, Paul Brousse Hospital, Villejuif, France. 6. Hepatology and Pediatrics Department, AP-HP, Kremlin-Bicètre Hospital, Kremlin-Bicètre, France. 7. Hepatology and Pediatrics Department, AP-HP, Necker Hospital, Paris, France. 8. Hepatology and Gastroenterology Department, CHU Besancon, Besancon, France. 9. Neurology Department, CHU Marseille, Marseille, France. 10. Neurology Department, CHU Toulouse, Toulouse, France. 11. Biostatistics Unit, EA2694, CHRU Lille, Lille, France. 12. Mathematics Laboratory, UMR CNRS 8524, Lille, France.
Abstract
BACKGROUND AND PURPOSE: The severity of Wilson's disease (WD) is linked to free copper accumulating in the liver and brain. Exchangeable copper (CuEXC) is a new technique to determine plasmatic copper and is useful in the diagnosis of WD. It is hypothesized that it may also enable a good evaluation of extra-hepatic involvement and its severity. METHODS: Forty-eight newly diagnosed WD patients were prospectively evaluated using hepatic, neurological, ophthalmological and brain magnetic resonance imaging (MRI) scores. Three phenotypic presentations were distinguished: pre-symptomatic, hepatic and extra-hepatic. CuEXC was determined in addition to standard copper assays before decoppering therapy. Correlations between biological parameters and the different scores were determined and compared in the hepatic and extra-hepatic groups. RESULTS: Extra-hepatic patients had significantly higher CuEXC values than those with the hepatic form (P < 0.0001). The overall ability of CuEXC to separate the two forms was satisfactory, with an area under the curve of 0.883 (95% confidence interval 0.771-0.996) and an optimal threshold for extra-hepatic diagnosis of 2.08 μmol/l (sensitivity 85.7%; specificity 94.1%). In extra-hepatic patients, CuEXC was the only biological marker to be positively correlated with the Unified Wilson Disease Rating Score (r = 0.45, P = 0.016), the Kayser-Fleischer ring score (r = 0.46, P = 0.014) and the brain MRI score (r = 0.38, P = 0.048), but it was not correlated with the hepatic score. CONCLUSIONS: Exchangeable copper determination is useful when diagnosing WD as a value >2.08 μmol/l is indicative of the severity of the extra-hepatic involvement. In the case of purely hepatic presentation, atypical or mild neurological signs, it should encourage physicians to search for lesions in the brain and eyes.
BACKGROUND AND PURPOSE: The severity of Wilson's disease (WD) is linked to free copper accumulating in the liver and brain. Exchangeable copper (CuEXC) is a new technique to determine plasmatic copper and is useful in the diagnosis of WD. It is hypothesized that it may also enable a good evaluation of extra-hepatic involvement and its severity. METHODS: Forty-eight newly diagnosed WDpatients were prospectively evaluated using hepatic, neurological, ophthalmological and brain magnetic resonance imaging (MRI) scores. Three phenotypic presentations were distinguished: pre-symptomatic, hepatic and extra-hepatic. CuEXC was determined in addition to standard copper assays before decoppering therapy. Correlations between biological parameters and the different scores were determined and compared in the hepatic and extra-hepatic groups. RESULTS: Extra-hepatic patients had significantly higher CuEXC values than those with the hepatic form (P < 0.0001). The overall ability of CuEXC to separate the two forms was satisfactory, with an area under the curve of 0.883 (95% confidence interval 0.771-0.996) and an optimal threshold for extra-hepatic diagnosis of 2.08 μmol/l (sensitivity 85.7%; specificity 94.1%). In extra-hepatic patients, CuEXC was the only biological marker to be positively correlated with the Unified Wilson Disease Rating Score (r = 0.45, P = 0.016), the Kayser-Fleischer ring score (r = 0.46, P = 0.014) and the brain MRI score (r = 0.38, P = 0.048), but it was not correlated with the hepatic score. CONCLUSIONS: Exchangeable copper determination is useful when diagnosing WD as a value >2.08 μmol/l is indicative of the severity of the extra-hepatic involvement. In the case of purely hepatic presentation, atypical or mild neurological signs, it should encourage physicians to search for lesions in the brain and eyes.
Authors: Anna Członkowska; Tomasz Litwin; Petr Dusek; Peter Ferenci; Svetlana Lutsenko; Valentina Medici; Janusz K Rybakowski; Karl Heinz Weiss; Michael L Schilsky Journal: Nat Rev Dis Primers Date: 2018-09-06 Impact factor: 52.329
Authors: Anna Członkowska; Tomasz Litwin; Karolina Dzieżyc; Michal Karliński; Johan Bring; Carl Bjartmar Journal: BMC Neurol Date: 2018-04-05 Impact factor: 2.474
Authors: Sabine Borchard; Stefanie Raschke; Krzysztof M Zak; Carola Eberhagen; Claudia Einer; Elisabeth Weber; Sandra M Müller; Bernhard Michalke; Josef Lichtmannegger; Albrecht Wieser; Tamara Rieder; Grzegorz M Popowicz; Jerzy Adamski; Martin Klingenspor; Andrew H Coles; Ruth Viana; Mikkel H Vendelbo; Thomas D Sandahl; Tanja Schwerdtle; Thomas Plitz; Hans Zischka Journal: Life Sci Alliance Date: 2021-12-02
Authors: Samuel Shribman; Carolin Heller; Maggie Burrows; Amanda Heslegrave; Imogen Swift; Martha S Foiani; Godfrey T Gillett; Emmanuel A Tsochatzis; James B Rowe; Alex Gerhard; Chris R Butler; Mario Masellis; Fion Bremner; Alison Martin; Lynne Jung; Paul Cook; Henrik Zetterberg; Oliver Bandmann; Jonathan D Rohrer; Thomas T Warner Journal: Mov Disord Date: 2020-10-20 Impact factor: 9.698